Tempest Therapeutics, Inc. Cash Flow Statement
TPST|3 years of annual SEC 10-K data (FY2015-FY2017)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 3 fiscal years. All figures from audited SEC 10-K filings.
Tempest Therapeutics, Inc. used $50M in operating cash flow and negative free cash flow of $56M in FY2017.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2017 | FY2016 | FY2015 |
|---|---|---|---|
| Net Income | -$73.2M | -$49.5M | -$29.0M |
| Depreciation & Amortization | $1.3M | $450.0K | $231.0K |
| Operating Cash Flow | -$50.3M | -$30.6M | -$18.1M |
| Capital Expenditures | $5.2M | $2.8M | $719.0K |
| Free Cash Flow | -$55.5M | -$33.4M | -$18.8M |
| FCF Margin | -20041.5% | - | - |